OHR Pharmaceutical Company Profile (NASDAQ:OHRP)

About OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical logo

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $23.37 million
  • Outstanding Shares: 35,961,000
Average Prices:
  • 50 Day Moving Avg: $0.71
  • 200 Day Moving Avg: $1.43
  • 52 Week Range: $0.60 - $4.05
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.46
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.72 per share
  • Price / Book: 0.90
Profitability:
  • EBIDTA: ($27,500,000.00)
  • Return on Equity: -80.25%
  • Return on Assets: -70.12%
Debt:
  • Current Ratio: 2.96%
  • Quick Ratio: 2.96%
Misc:
  • Average Volume: 336,759 shs.
  • Beta: 0.92
  • Short Ratio: 2.13
 

Frequently Asked Questions for OHR Pharmaceutical (NASDAQ:OHRP)

What is OHR Pharmaceutical's stock symbol?

OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."

How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) released its earnings results on Thursday, May, 11th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.09. View OHR Pharmaceutical's Earnings History.

Where is OHR Pharmaceutical's stock going? Where will OHR Pharmaceutical's stock price be in 2017?

3 equities research analysts have issued 1-year target prices for OHR Pharmaceutical's shares. Their forecasts range from $10.00 to $13.00. On average, they anticipate OHR Pharmaceutical's stock price to reach $11.50 in the next twelve months. View Analyst Ratings for OHR Pharmaceutical.

Who are some of OHR Pharmaceutical's key competitors?

Who owns OHR Pharmaceutical stock?

OHR Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (4.20%), Vanguard Group Inc. (2.24%), Bailard Inc. (1.25%), Renaissance Technologies LLC (0.64%) and Geode Capital Management LLC (0.43%). Company insiders that own OHR Pharmaceutical stock include Jason Scott Slakter, Orin Hirschman and Samuel Backenroth. View Institutional Ownership Trends for OHR Pharmaceutical.

Who bought OHR Pharmaceutical stock? Who is buying OHR Pharmaceutical stock?

OHR Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, Renaissance Technologies LLC, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought OHR Pharmaceutical stock in the last two years include Jason Scott Slakter, Orin Hirschman and Samuel Backenroth. View Insider Buying and Selling for OHR Pharmaceutical.

How do I buy OHR Pharmaceutical stock?

Shares of OHR Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of OHR Pharmaceutical stock cost?

One share of OHR Pharmaceutical stock can currently be purchased for approximately $0.65.

Analyst Ratings

Consensus Ratings for OHR Pharmaceutical (NASDAQ:OHRP) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $11.50 (1,669.23% upside)

Analysts' Ratings History for OHR Pharmaceutical (NASDAQ:OHRP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/17/2017HC WainwrightSet Price TargetBuy$10.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
6/16/2016Roth CapitalReiterated RatingBuy$13.00N/AView Rating Details
5/16/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for OHR Pharmaceutical (NASDAQ:OHRP)
Earnings by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)
Earnings History by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q2 2017($0.30)($0.21)ViewN/AView Earnings Details
2/14/2017Q117($0.19)($0.21)ViewListenView Earnings Details
5/10/2016Q2($0.18)($0.17)ViewListenView Earnings Details
12/10/2015Q415($0.20)($0.13)ViewListenView Earnings Details
5/11/2015Q215($0.17)($0.12)ViewListenView Earnings Details
2/9/2015Q115($0.20)($0.18)ViewN/AView Earnings Details
12/22/2014($0.10)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OHR Pharmaceutical (NASDAQ:OHRP)
Current Year EPS Consensus Estimate: $-1.00 EPS
Next Year EPS Consensus Estimate: $-1.42 EPS

Dividends

Dividend History for OHR Pharmaceutical (NASDAQ:OHRP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OHR Pharmaceutical (NASDAQ:OHRP)
Insider Ownership Percentage: 17.70%
Institutional Ownership Percentage: 9.13%
Insider Trades by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)
Institutional Ownership by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)
Insider Trades by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2017Orin HirschmanDirectorBuy142,858$0.70$100,000.60View SEC Filing  
4/10/2017Samuel BackenrothCFOBuy71,429$0.70$50,000.30View SEC Filing  
6/20/2016Jason Scott SlakterCEOBuy8,786$2.85$25,040.10View SEC Filing  
6/20/2016Samuel BackenrothCFOBuy2,468$2.84$7,009.12View SEC Filing  
5/25/2016Jason Scott SlakterCEOBuy3,682$3.11$11,451.02View SEC Filing  
5/24/2016Jason Scott SlakterCEOBuy28,068$3.15$88,414.20View SEC Filing  
5/23/2016Samuel BackenrothCFOBuy2,500$3.17$7,925.00View SEC Filing  
4/11/2016Jason Scott SlakterCEOBuy6,250$3.35$20,937.50View SEC Filing  
3/7/2016Jason Scott SlakterCEOBuy6,250$3.63$22,687.50View SEC Filing  
2/22/2016Jason Scott SlakterCEOBuy6,250$3.11$19,437.50View SEC Filing  
1/19/2016Jason Scott SlakterCEOBuy6,250$3.62$22,625.00View SEC Filing  
12/7/2015Jason Scott SlakterCEOBuy3,000$4.07$12,210.00View SEC Filing  
11/3/2015Jason Scott SlakterCEOBuy13,350$3.00$40,050.00View SEC Filing  
2/6/2015Irach B TaraporewalaCEOBuy3,705$6.75$25,008.75View SEC Filing  
2/6/2015June Sherie AlmenoffDirectorBuy6,000$6.75$40,500.00View SEC Filing  
2/6/2015Samuel BackenrothCFOBuy1,500$6.75$10,125.00View SEC Filing  
9/3/2014June Sherie AlmenoffDirectorBuy2,200$8.08$17,776.00View SEC Filing  
7/2/2014Ira A GreensteinDirectorBuy1,000$8.40$8,400.00View SEC Filing  
6/26/2014June Sherie AlmenoffDirectorBuy3,200$8.34$26,688.00View SEC Filing  
6/25/2014Thomas M RiedhammerDirectorBuy6,900$7.39$50,991.00View SEC Filing  
4/9/2014Ira A GreensteinDirectorBuy2,500$10.20$25,500.00View SEC Filing  
4/8/2014June Sherie AlmenoffDirectorBuy5,500$10.25$56,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for OHR Pharmaceutical (NASDAQ:OHRP)
Latest Headlines for OHR Pharmaceutical (NASDAQ:OHRP)
Source:
DateHeadline
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) Issues Earnings Results
www.americanbankingnews.com - May 12 at 11:06 AM
streetinsider.com logoOhr Pharmaceutical (OHRP) Announces Appointment of Mike Ferguson as Chairman of the Board of Directors
www.streetinsider.com - May 12 at 12:32 AM
cnbc.com logoOHR reports 2Q loss
www.cnbc.com - May 11 at 7:30 PM
finance.yahoo.com logoInvestor Network: Ohr Pharmaceutical Inc to Host Earnings Call
finance.yahoo.com - May 11 at 7:30 PM
finance.yahoo.com logoOhr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings
finance.yahoo.com - May 11 at 7:30 PM
finance.yahoo.com logoOhr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors
finance.yahoo.com - May 11 at 7:30 PM
finance.yahoo.com logoOhr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11
finance.yahoo.com - May 9 at 11:20 AM
americanbankingnews.com logo-$0.30 EPS Expected for OHR Pharmaceutical Inc (OHRP) This Quarter
www.americanbankingnews.com - May 3 at 12:06 AM
americanbankingnews.com logoOHR Pharmaceutical (OHRP) Receiving Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 2 at 9:52 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Affect OHR Pharmaceutical (OHRP) Stock Price
www.americanbankingnews.com - April 29 at 6:11 PM
americanbankingnews.com logoOHR Pharmaceutical (OHRP) Earns Coverage Optimism Score of 0.05
www.americanbankingnews.com - April 21 at 6:04 PM
finance.yahoo.com logoOhr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session
finance.yahoo.com - April 18 at 9:59 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Extremely Likely to Effect OHR Pharmaceutical (OHRP) Stock Price
www.americanbankingnews.com - April 17 at 1:47 PM
americanbankingnews.com logoOHR Pharmaceutical (OHRP) Getting Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 14 at 2:24 PM
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) CFO Samuel Backenroth Buys 71,429 Shares
www.americanbankingnews.com - April 13 at 2:26 PM
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) Director Purchases $100,000.60 in Stock
www.americanbankingnews.com - April 13 at 2:26 PM
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) Short Interest Up 14.6% in March
www.americanbankingnews.com - April 13 at 12:34 PM
finance.yahoo.com logoOhr Pharmaceutical Provides Update on Squalamine Study
finance.yahoo.com - April 11 at 6:54 PM
americanbankingnews.com logoZacks: Brokerages Anticipate OHR Pharmaceutical Inc (OHRP) to Post -$0.30 Earnings Per Share
www.americanbankingnews.com - April 11 at 6:04 PM
rttnews.com logoAXON Names New CEO, ANTH Awaits Data In Q3, Nicox Gets 2nd Chance From FDA
www.rttnews.com - April 11 at 10:44 AM
streetinsider.com logoOhr Pharmaceutical (OHRP) Amends Trial of Squalamine in Wet-AMD to Enable Efficacy Analyses by End of 2017 or Early 2018
www.streetinsider.com - April 11 at 10:44 AM
finance.yahoo.com logoOhr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
finance.yahoo.com - April 10 at 6:33 PM
finance.yahoo.com logoOhr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
finance.yahoo.com - April 10 at 6:33 PM
finance.yahoo.com logoOhr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - April 7 at 11:42 AM
finance.yahoo.com logoOhr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
finance.yahoo.com - April 7 at 11:42 AM
americanbankingnews.com logoZacks: OHR Pharmaceutical Inc (OHRP) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - March 31 at 1:58 PM
finance.yahoo.com logoOhr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference
finance.yahoo.com - March 2 at 7:11 PM
biz.yahoo.com logoOHR PHARMACEUTICAL INC Files SEC form 8-K, Other Events
biz.yahoo.com - February 22 at 7:08 PM
investopedia.com logoOhr Reports 4Q Loss, Suspends Trial (OHRP)
www.investopedia.com - February 16 at 6:34 PM
us.rd.yahoo.com logoOhr Pharmaceutical Reports 4Q Loss, Suspends Trial
us.rd.yahoo.com - February 16 at 6:34 PM
seekingalpha.com logoOhr Pharmaceutical's (OHRP) CEO Jason Slakter on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 15 at 3:28 AM
finance.yahoo.com logoOhr Pharmaceutical Announces Strategic Update and Fiscal First Quarter 2017 Earnings
finance.yahoo.com - February 14 at 10:26 PM
biz.yahoo.com logoOHR PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
biz.yahoo.com - February 14 at 10:26 PM
biz.yahoo.com logoQ1 2017 OHR Pharmaceutical Inc Earnings Release - Before Market Open
biz.yahoo.com - February 14 at 10:26 PM
finance.yahoo.com logo7:08 am Ohr Pharma announces it remains in active ongoing discussions with potential pharma partners and, thus, has paused enrollment in the Phase 3 clinical trial of its lead candidate squalamine; also reports Q4 loss of ($0.21) vs ($0.19)
finance.yahoo.com - February 14 at 10:26 PM
globenewswire.com logoOhr Pharmaceutical to Announce First Quarter 2017 Financial Results on February 14 - GlobeNewswire (press release)
globenewswire.com - February 14 at 1:15 AM

Social

OHR Pharmaceutical (OHRP) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff